May 6, 2019

Novus: Protease shown to reduce subclinical necrotic enteritis in broilers


Novus International, Inc., a leader in animal nutrition and health solutions, recently shared research on its CIBENZA® EP150 enzyme feed additive, with a presentation on the use of the novel protease to reduce subclinical necrotic enteritis in broilers during the Intestinal Health Scientific Interest Group (IHSIG) symposium in Rome, Italy in April.


Marisol Castillo, senior technical services manager for Novus Europe, presented the latest results looking at how protein-rich diets significantly reduce performance in broilers compared to industry-accepted levels of protein.


She demonstrated that poultry whose protein-heavy feed was supplemented with CIEBENZA® EP150, which includes a combination of protease enzyme and Bacillus licheniformis spores, were able to cope better and maintain bodyweights at a similar level to the birds fed the normal protein diets.


"These findings are in line with our understanding of the negative effect on performance that can happen due to bacterial overgrowth in the hindgut in birds fed excess protein," said Silvia Peris, Novus' head of technical services in Europe and the Middle East. "The birds fed the high protein diet had a significant increase of Clostridium perfringens counts in the ileum (predisposing to the occurrence necrotic enteritis). The addition of the combined protease and the spores was able to reduce that challenge significantly.

Castillo concluded that Clostridium perfringens overgrowth can be reduced by lowering the dietary protein content or, in diets where excess protein is not easily discernable, by adding CIBENZA® EP150 to the diet. In this gut health challenge model, supplementing broiler diets with CIBENZA® EP150 improved intestinal barrier function.


More than 760 participants attended the keynote presentations led by internationally-known speakers who provided the latest scientific information on intestinal health. This symposium's edition hosted more than 125 scientific abstracts from more than 50 countries.


- Novus